1. Jung, T, Stingl, G. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol 2008; 122: 1074–1081.
Google Scholar | Crossref | Medline2. Holm, EA, Wulf, HC, Thomassen, L, et al. Instrumental assessment of atopic eczema: validation of transepidermal water loss, stratum corneum hydration, erythema, scaling, and edema. J Am Acad Dermatol 2006; 55: 772–780.
Google Scholar | Crossref | Medline3. Seidenari, S, Giusti, G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 1995; 75: 429–433.
Google Scholar | Medline4. Tagami, H, Yoshikuni, K. Interrelationship between water barrier and reservoir functions of pathologic stratum corneum. Arch Dermatol 1985; 121: 642–645.
Google Scholar | Crossref | Medline5. Kim, DW, Park, JY, Na, GY, et al. Correlation of clinical features and skin barrier function in adolescent and adult patients with atopic dermatitis. Int J Dermatol 2006; 45: 698–701.
Google Scholar | Crossref | Medline6. Leung, DYM, Berdyshev, E, Goleva, E. Cutaneous barrier dysfunction in allergic diseases. J Allergy Clin Immunol 2020; 145: 1485–1497.
Google Scholar | Crossref | Medline7. Langan, SM, Irvine, AD, Weidinger, S. Atopic dermatitis [Erratum in: Lancet 2020; 396: 758]. Lancet 2020; 396: 345–360.
Google Scholar | Crossref | Medline8. Yang, G, Seok, JK, Kang, HC, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci 2020; 21: 2867.
Google Scholar9. Palmer, CN, Irvine, AD, Terron-Kwiatkowski, A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441–446.
Google Scholar | Crossref | Medline10. Thyssen, JP, Kezic, S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2014; 134: 792–799.
Google Scholar | Crossref | Medline11. Pellerin, L, Henry, J, Hsu, CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol 2013; 131: 1094–1102.
Google Scholar | Crossref | Medline12. Di Nardo, A, Wertz, P, Giannetti, A, et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998; 78: 27–30.
Google Scholar | Crossref | Medline13. Jungersted, JM, Scheer, H, Mempel, M, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 2010; 65: 911–918.
Google Scholar | Crossref | Medline14. Elias, PM, Wakefield, JS. Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2014; 134: 781–791.e1.
Google Scholar | Crossref | Medline15. Wolf, R, Wolf, D. Abnormal epidermal barrier in the pathogenesis of atopic dermatitis. Clin Dermatol 2012; 30: 329–334.
Google Scholar | Crossref | Medline16. Bergmann, S, von Buenau, B, Vidal-Y-Sy, S, et al. Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently. Sci Rep 2020; 10: 2024.
Google Scholar | Crossref17. Seegraber, M, Srour, J, Walter, A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018; 2: 467–474.
Google Scholar | Crossref18. De Bruin-Weller, M, Thaçi, D, Smith, CH, et al. Dupilumab with concomitant topical corticosteroids in adult patients with AD who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFE). Br J Dermatol 2018; 178: 1083–1101.
Google Scholar | Medline19. Ferrucci, S, Casazza, G, Angileri, L, et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med 2020; 9: 791.
Google Scholar | Crossref20. Guttman-Yassky, E, Bissonnette, R, Ungar, B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 143: 155–172.
Google Scholar | Crossref | Medline21. Hon, KL, Wong, KY, Leung, TF, et al. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD Index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008; 9: 45–50.
Google Scholar | Crossref | Medline22. Nuutinen, J, Alanen, E, Autio, P, et al. A closed unventilated chamber for the measurement of transepidermal water loss. Skin Res Technol 2003; 9: 85–89.
Google Scholar | Crossref | Medline23. De Paepe, K, Houben, E, Adam, R, et al. Validation of the VapoMeter, a closed unventilated chamber system to assess transepidermal water loss vs. The open chamber Tewameter. Skin Res Technol 2005; 11: 61–69.
Google Scholar | Crossref | Medline24. Akdeniz, M, Gabriel, S, Lichterfeld-Kottner, A, et al. Transepidermal water loss in healthy adults: a systematic review and meta-analysis update. Br J Dermatol 2018; 179: 1049–1055.
Google Scholar | Crossref | Medline25. Hon, KL, Leung, AK, Barankin, B. Barrier repair therapy in atopic dermatitis: an overview. Am J Clin Dermatol 2013; 14: 389–399.
Google Scholar | Crossref | Medline26. Park, KY, Kim, DH, Jeong, MS, et al. Changes of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide-dominant emollient in patients with atopic dermatitis. J Korean Med Sci 2010; 25: 766–771.
Google Scholar | Crossref | Medline27. Chamlin, SL, Kao, J, Frieden, IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47: 198–208.
Google Scholar | Crossref | Medline28. Cristaudo, A, Pigliacelli, F, Sperati, F, et al. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: an observational study. Skin Res Technol 2021; 27: 810–813.
Google Scholar | Crossref | Medline29. Rohner, MH, Thormann, K, Cazzaniga, S, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy 2021; 76: 1268–1270.
Google Scholar | Crossref | Medline